Article
Unveiling the vulnerabilities of synthetic lethality in triple-negative breast cancer.
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico - 1 Nov 2023
Chatterjee Prarthana, Karn Rohit, Isaac Arnold Emerson, Ray Smita
Abstract excerpt
Triple-negative breast cancer (TNBC) is the most invasive molecular subtype of breast cancer (BC), accounting for about nearly 15% of all BC cases reported annually. The absence of the three major BC hormone receptors, Estrogen (ER), Progesterone (PR), and Human Epidermal Growth Factor 2 (HER2) receptor, accounts for the characteristic "Triple negative" phraseology. The absence of these marked receptors makes...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.